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Enteric neural crest cells (NCC) are multipotent progenitors which give rise to neurons and glia of the enteric nervous system (ENS) during
fetal development. Glial cell line-derived neurotrophic factor (GDNF)/RET receptor tyrosine kinase (Ret) signaling is indispensable for their
survival, migration and differentiation. Using microarray analysis and isolated NCCs, we found that 45 genes were differentially expressed after
GDNF treatment (16 h), 29 of them were up-regulated including 8 previously undescribed genes. Prokineticin receptor 1 (PK-R1), a receptor for
Prokineticins (Prok), was identified in our screen and shown to be consistently up-regulated by GDNF in enteric NCCs. Further, PK-R1 was
persistently expressed at a lower level in the enteric ganglions of the c-Ret deficient mice when compared to that of the wild-type littermates.
Subsequent functional analysis showed that GDNF potentiated the proliferative and differentiation effects of Prok-1 by up-regulating PK-R1
expression in enteric NCCs. In addition, expression analysis and gene knock-down experiments indicated that Prok-1 and GDNF signalings shared
some common downstream targets. More importantly, Prok-1 could induce both proliferation and expression of differentiation markers of c-Ret
deficient NCCs, suggesting that Prok-1 may also provide a complementary pathway to GDNF signaling. Taken together, these findings provide
evidence that Prok-1 crosstalks with GDNF/Ret signaling and probably provides an additional layer of signaling refinement to maintain
proliferation and differentiation of enteric NCCs.
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doi:10.1016/j.bbamcr.2007.09.005They are similar to embryonic stem cells in that they have a high
degree of plasticity and are able to give rise to neurons and glia
of the peripheral nervous system (PNS), skeleton and smooth
muscle of aortic arch, chondrocytes, osteocytes, melanocytes,
chromaffin cells, supporting cells and hormone producing cells
in various organs.
Vagal and sacral NCCs contribute to neurons and glia of the
enteric nervous system (ENS) during fetal development. Once
they reach the gut, NCCs proliferate, differentiate and colonize
the developing bowel. ENS development is then completed by
establishing synaptic networks among neurons and glia, which
regulate the peristalsis and secretory activity of the bowel.
Appropriate pool size of NCCs is crucial for the normal and
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NCCs may result in congenital colonic aganglionosis, known as
Hirschsprung disease (HSCR) or megacolon [2].
Gial cell line-derived neurotophic factor (GDNF) is one of the
most critical factorsmediating the enteric NCC pool for the proper
ENS development. GDNFbinds on the RET tyrosine kinase and a
glycosylphosphatidylinositol (GPI)-anchored ligand binding
subunit (GFRα) to confer its survival, differentiation and mig-
ration signalings for enteric NCCs. In humans, mutations in RET
account for approximately 50% of familial HSCR cases [3,4], but
mutations of the Gdnf and GFRα-1 genes are not a common
aetiological event in HSCR [5]. Conversely, mice deficient in
eitherRet (Retk−),Gdnf (Gdnf−) orGfrα1 (Gfrα1−) have complete
intestinal aganglionosis [6–13], suggestingGDNF/RETsignaling
is indispensable for ENS development.
Recent advance in microarray technology facilitates the id-
entification of genes implicated in ENS development. Molecular
characterization using microarray analysis to compare gut NCCs
to whole-fetus RNA identified a panel of genes uniquely or
highly expressed in the NCCs [14]. It includes numerous genes
linked to HSCR, including Ret, Gfra1, EDNRB and Sox10,
further confirming the biological significances of these path-
ways in ENS development. More recently, expression profiling
studies on developing guts of c-Ret mutant mice (Retk−/ Retk)
have been performed by two different groups [15,16]. c-Ret
mutant mice display a complete intestinal aganglionosis [6],
therefore, it is a useful model for identification of genes speci-
fically expressed in ENS. In their screens, they have identified a
large cohort of candidate ENS marker genes within the mam-
malian gut, and several of them have been proven to have
biological implications. In particular, Arhgef3 and Ctnnal1
located in HSCR susceptibility loci, 3p21 and 9q31, respectively
[15]; and a synaptosomal associated protein called Snap 25
mediates the NCC migration and neurite extension [16]. After
careful comparisons of these reports, we found that only nine-
teen genes are common in these two studies. The deviations may
be due to stage difference of the mutant mice used in their studies
and therefore may represent the stage-specific ENS markers.
Instead of ENS markers, we screened for the GDNF posi-
tively regulated genes. To achieve this, we have performed
microarray analysis using the purified enteric NCCs. We found
that 45 genes are differentially expressed and 29 of them are up-
regulated upon the GDNF treatment (16 h). Among these 29 up-
regulated genes, 72% of them (21/29) have also been found to be
reduced in Retmutant mice (Retk−/ Retk) [15,16]. In addition, we
have also identified eight genes, including a G-protein coupled
receptor called GPR73 or Prokineticin receptor -1 (PK-R1),
which have not been described in the previous screens with Ret
mutant mice [15,16]. Here, we focused, in particular, on a cross-
talk between GDNF/Ret and Prokineticin-1 (Prok-1) which has
been recently demonstrated via PK-R1 to mediate differentiation
and proliferation of enteric NCCs [17]. Therefore, in this study
we have revealed not only a panel of new candidate genes
implicated in GDNF/Ret signaling, but also a new pathway in
which Prok-1 may provide an additional layer of signaling
refinement to maintain proliferation and differentiation of
enteric NCCs.2. Materials and methods
2.1. Animals
Mice carrying theRet.k−mutation were crossed randomlywith a mixed genetic
background [11]. The genotype of embryos and animals was determined by PCR,
as has been described previously [11]. The day of a vaginal plug observed was
considered E0.5. For cultures of enteric NCCs, wild-type ICR, Ret.k−mutant mice
and their wild-type littermates were used.
2.2. NCC culture
E11.5 ICRmouse guts (from stomach to hindgut)were dissected inL15medium
(Invitrogen, Rockville, MD). Guts were washed with Ca2+ and Mg2+ free PBS and
digested with collagenase/dispase (0.2 μg/ml each; 37 °C for 10min). Digested guts
were triturated into single cells and filtered through cell strainers (100 μm and then
40 μm). NCCs were then isolated from the mesenchymal cells using MACS®
separator (Miltenyi Biotec, BergischGladbach,Germany) and anti-p75NTR antibody
(Abcam, MA, USA) according to the manufacturer's protocol. Isolated cells were
resuspended in NCCmedium, DMEM containing 15%Chick embryo extract (SIL,
Sussex, UK), FGF (20 ng/ml, Sigma, St. Louis, MO), EGF (20 ng/ml, Sigma),
Retinoic acid (35 ng/ml, Sigma), N2 (1%), B27 (2%, Invitrogen), β-mercaptoetha-
nol (50mM, Sigma), and plated onto poly-D-lysine- and fibronectin (20 μg/ml each,
Life Technologies Inc.)-coated wells according to a previously-described protocol
[17,18]. TheNCCswere seeded at clonal density (1×105 cells per each 35-mmwells
and 5×103 cells per each 20-mmwell). Subsequent immunostaining analysis using
anti Ret antibody (Neuromics, MN, USA) showed that the purity of isolated NCC is
approximately 80%. The differentiation capability of isolated cells has also been
tested in presence of GDNF (50 ng/ml) (supplement 1).
Ret.k−mutant mice: Esophagus and stomach of the homozygous Ret.k−mice
and their wild-type littermates were dissected out and digested as stated above.
Due to the limited amount of mutant embryos, the NCCs were enriched by
multiple replating as described [17] instead of being isolated with cell sorting
system used in the wild-type ICR mice. The digested cells from one individual
gut were first grown in a 5-mm well (48 well plate) for 3 days with the NCC
medium. After genotyping, the NCCs of the same genotype (approximate from 6
to 8 mutant embryos) were pooled together and grew at the clonal density. The
third passage of the NCCs was used for the subsequent experiments. NCCs were
stained with p75NTR antibody to assess the purity of culture. The purity of the
third passage of NCC culture was higher than 80%.
2.3. Microarray analysis
NCCs were cultured in presence or absence of GDNF (50 ng/ml) for 8 and 16 h.
RNA was then extracted from treated and untreated NCCs using TRIzol reagent
(Invitrogen) and purified by RNeasy mini kit (Qiagen, Hilden, Germany). Three
independent experiments have been performed. Three 5 μg total RNA samples from
treated and untreated NCCs were used to prepare material for hybridization of six
GeneChipMouse Expression Set Genome 430 2.0 arrays (Affymetrix) according to
the manufacturer's protocol. Hybridization, scanning and generation of raw
expression data were performed by a core facility at the Genome Research Center,
University of Hong Kong. Data analysis was performed by using GENE SPRING 7
software (Agilent Technologies, Palo Alto, CA).
2.4. Reverse Transcription-PCR (RT-PCR)
Total RNAwas isolated from NCCs by TRIzol reagent (Invitrogen) and reverse
transcribed in 20μl reaction systemusing SuperScript™RNAAmplification System
(Invitrogen), in accordance with the manufacturer's instructions. PCR reactions were
performed using specific primers (Table 1). All the PCRs were performed separately
and in the linear range of amplification (25–35 cycles). The product bands were then
scanned for relative expression by comparing with that of the standard, β-actin.
2.5. Quantitative RT-PCR
RNA for RT-PCR was extracted from NCCs using TRIzol Reagent
(Invitrogen) and reverse transcribed in 20 μl as above. Quantitative PCR was
Table 1
Sequence information on PCR primers
Gene Primer sequence Product size (bp)
Primers for PCR
PK-R1 Forward: 5′TGTGCGCCTCTGTCAACTAC3′ 506
Reverse: 5′CGACGATAGTGAAGCCATA 3′
Ret Forward: 5′CGGGACTTAGCTGCCAGGAAC3′ 421
Reverse: 5′TGCTCTTGACCATCATCT3′
Olfm1 Forward: 5′AAACCGCCATGTAGTGGATA 3′ 432
Reverse: 5′ TACCACCTTGGGGGATAACA 3′
VIP Forward: 5′GTAGGCTGGATGACAGGAATCG 3′ 302
Reverse: 5′ GTAGTTATCTGTGAAGACGGC 3′
β- actin Forward: 5′ GAGAGGGAAATCGTGCGTGAC 3′ 534
Reverse: 5′ AGCTCAGTAACAGTCCGCCTA 3′
Primers for qPCR
VIP Forward: 5′ GCATGCTGATGGAGTTTTCA 3′ 145
Reverse: 5′ GGCATCAGAGTGTCGTTTGA 3′
Stmn2 Forward: 5′ GACATGTCGGGTGGCTTATC 3′ 130
Reverse: 5′ TAATGCAGCAACCAGCTCAC 3′
Scg3 Forward: 5′ CGAGAATCAGGATGGGAAAA 3′ 149
Reverse: 5′ CTTCCCTGTGGGGGTTAGTT 3′
Galn Forward: 5′ GAGGCAGCGTTATCCTGCTA 3′ 216
Reverse: 5′ GGTCTCCTTTCCTCCACCTC 3′
Gdap1 Forward: 5′ ATTGCCAAACAGAAGCGACT 3′ 146
Reverse: 5′ CCCTCCTCTGGAGTTTCCTC 3′
Olfm1 Forward: 5′ CAGATGAAAGGCCTGGAGAC 3′ 139
Reverse: 5′ GCATCGGCCTTGTACTCTTC 3′
PK-R1 Forward: 5′ ACAGAGCAGATCCGCCG 3′ 116
Reverse: 5′ CGCACGATAGTGAAGCCATA 3′
18S Forward: 5′ CGGCTACCACATCCAAGGA 3′ 183
Reverse: 5′ GCTGGAATTACCGCGGCT 3′
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consisted of 1× mastermix, forward and reverse primers. The reaction mix
(18 μl) was aliquoted into tubes and 2 μl cDNA was added. Duplicated 20 μl
samples plus positive and negative controls were placed in a PCR plate and
wells were sealed with optical caps. The PCRs were carried out using an ABI
Prism 7900 (Applied Biosystems). All primers sequences were listed in Table 1.
Data were analyzed and processed using Sequence Detector version 1.6.3
(Applied Biosystems) in accordance with the manufacturer's instructions.
Primers were optimized and the linearity of the results validated in serial dilution
of a cDNA pool. Results were expressed relative to an internal positive standard
(cDNA obtained from a single sample of NCCs) included in all reactions. 18S
was used as the internal control.
2.6. Immunohistochemistry
Immunohistochemical study was performed on Ret.k mouse embryos at
embryonic stage 14.5 (E14.5). Mouse embryonic samples were fixed and
embedded in paraffin, subsequently sectioned and mounted on glass slides. Rabbit
polyclonal antiserum to hPK-R1 (1:150) (Lifespan Biosciences, Inc, Seattle, WA);
β-tubulin, Tuj1 (1:200, Covance, Denver, PA) were used for immunohistochem-
istry. For histological analysis, paraffin sections of mouse embryos (stomach) were
rehydrated using standard protocols and microwaved for 10min in 10mM sodium
citrate pH 6.0. Sections were then incubated with the antibodies followed by
incubation with secondary antibodies (Calbiochem, San Diego, CA) and mounted
with aqueous mounting media (Vector, Burlingame, CA).
2.7. BrdU incorporation and immunocytochemistry
BrdU incorporation was performed using In situ Cell Proliferation kit Fluos
(Roche, Indianapolis, IN). The cells were treated with recombinant mouse Prok-
1 (ED50 is 2–4 μg/ml, R&D, Minneapolis, MN) with concentrations of 4 μg/ml
[17], recombinant human GDNF (50 ng/ml, PeproTech, Rocky Hill, NJ) or in
combination for 24 h. BrdU was added 8–16 h before the termination of culture.Culture was fixed, blocked and incubated with anti-Ret (1:200, Neuromics) or
anti-p75NTR (1:2000, Chemicon) antibodies. The immunosignal was detected
using anti-goat IgG or anti-rabbit IgG conjugated with Texas Red. Genomic
DNAwas denatured in 4 N HCl (5 min at RT). After PBS washing, the cultures
were incubated with fluorescein-conjugated anti-BrdU antibody (Roche). Slides
were washed in PBS and mounted with aqueous mounting media.
2.8. RNA interference
PK-R1 siRNA (CAGAATTCTCTCAGAGAATAA) and a non-specific
siRNA control (AATTCTCCGAACGTGTCACGT) (Qiagen, GmbH, Hilden,
Germany) were used. 1×104 NCCs cells were transfected with PK-R1 or non-
specific siRNA using LipofectAMINE 2000 (Invitrogen) according to the
manufacturer's instructions. After 24 h, the cells were subjected to cell
proliferation and RNA extraction in the presence or absence of Prok-1.
2.9. Statistical Analysis
Differences among multiple treatment groups were analyzed by one-way
analysis of variance ANOVA followed by the Tukey posttest. A p value less than
0.05 represented a statistically-significant difference.
3. Results
3.1. Microarray screening for GDNF responsive genes in
enteric NCCs
To identify GDNF positively responsive genes, gene expres-
sion profiling was performed on Affymetrix microarrys using
untreated NCCs and NCCs treated with GDNF for 8 and 16 h.
These timepoints were chosen because the direct targets are able
to be distinguished from other secondary targets. Of the 39,000
genes represented on the chip, 29 and 16 genes (not including
EST) were consistently detected as upregulated and down-
regulated, respectively, 16 h after GDNF treatment in three
independent cultures, using 1.2 fold—change as a cut off level
(Table 2). Among these 29 up-regulated genes, 72% of them (21/
29) have also been reported as reduced in Retmutant mice (Retk−/
Retk) [15,16]. They include neuropeptides: vasoactive intestinal
polypeptide (VIP) and cocaine and amphetamine regulated
transcript (Cart); microtubule-associated proteins which may
function in both cell migration and axon outgrowth: tubulin beta
(Tubb3), transgelin 3 (Tagln3), microtubule-associated protein
tau (Mapt), superiorcervical ganglia neural specific 10 (Scgn10)
[15]; ganglioside-induced differentiation associated-protein-1
(Gdap1) [16]; secreted glycoprotein which is involved in
generation of the neural crest, olfactomedin 1 (olfm1/noelin-1)
[19]; and neuropeptide: Galanin (Galn) (Table 2, unbold). It is
noteworthy that only ten of these genes were found to be up-
regulated at 8 h after the treatment (Table 2).
In addition, we have also identified eight genes which have
not been previously described in Ret mutant mice that can also
be implicated in Ret/GDNF signaling, enteric neurogenesis or
neural crest growth. They represent components of signaling
pathways, including scaffolding proteins specifying the biolog-
ical function of MAP kinase pathway: mitogen activated protein
binding protein interacting protein (Mapbpip) and JNK inter-
acting protein (Mapk8ip2) [20,21]; transmembrane proteins:
potassium voltage-gated channel (Kcnd2), transmembrane
protein Bet (Bret) and G-protein couple receptor 73 (GPR73/
Fig. 1. GDNF elevates the expression of PK-R1 in enteric NCCs. (A) (Top) RT-
PCR analysis shows that the PK-R1 expression is up-regulated after GDNF
treatment. NCCs were culturedwithout (vehicle) or with 50 ng/ml GDNF for 8 and
16 h, and cells were harvested for the total RNA extraction and reverse
transcription. The expression of PK-R1 and β-actin was measured using RT-PCR.
PCR products were electrophoresed on 1% agarose gel, stained with ethidium
bromide, photographed. (Bottom) PK-R1 expression was analyzed by qPCR and
themean relative to untreated group (vehicle)was normalizedwith 18S expression.
The values reported in bar charts represent the mean±SEM of 3 independent
assays, each in duplicate. (B) GDNF up-regulates PK-R1 expression via Akt and
MAPK signaling pathways. RT-PCR analysis on the PK-R1 after GDNF treatment
in the presence ofMAPKandAkt inhibitors.NCCswere culturedwithout (vehicle)
or with 50 ng/ml GDNF and in the presence or absence of MAPK inhibitor
(PD98059, 20 μM) and PI-3-K inhibitor (LY294002), 10 μM for 24 h. (C) Down-
regulation of PK-R1 in the c-Ret deficient (Ret.k−) mice. Representative figures
from immunohistochemical analyzes using antibody specific to PK-R1 onWTand
c-Ret deficient mouse embryonic guts (E14.5). Neuroblasts derived from NCCs
were locatedwith Tuj1 antibody (Green). Consistently, the immunosignals specific
to PK-R1 protein in neuroblasts are weaker in the homozygous (Ret− /−) Ret.k−
mutants than in the wild-type (WT) mice.
Table 2
Genes were detected as upregulated after GDNF treatment
Gene
Symbol
Gene name Unigene Fold change
8 hours 16 hours
Pnliprp2 pancreatic lipase-related
protein 2
Mm.1230 – 6.96
Mapbpip mitogen activated protein
binding protein
interacting protein
Mm.41680 – 5.28
Kcnd2 potassium voltage-gated
channel, Shal-related
family, member 2
Mm.132309 – 2.64
Bcas2 breast carcinoma
amplified sequence 2
Mm.104919 – 2.64
Csnk casein kappa Mm.397 1.6 2.46
VIP vasoactive intestinal
polypeptide
Mm.98916 1.5 2.3
Gdap1 ganglioside-induced
differentiation-associated-
protein 1
Mm.18218 2.3
Bret transmembrane protein Bet Mm.39067 2.0 2.3
Gpr73
(PK-R1)
G protein-coupled receptor 73
(Prokineticin Receptor-1)
Mm.103800 1.7 2.14
Olfm1 olfactomedin 1 Mm.43278 – 2.14
Tesc tescalcin Mm.26378 – 2.14
Galn galanin Mm.4655 3.48 2.14
Stxbp3 syntaxin binding protein 3 Mm.12155.3 – 2
Mapk8ip2 JIP2 Mm.157741 – 2
Cart cocaine and amphetamine
regulated transcript
(Cart-pending),
Mm.75498 2.3 1.87
Elavl4 ELAV-like 4 Mm.3970 – 1.87
Scgn10
(Stmn2)
superiorcervical ganglia,
neural specific 10
Mm.29580 1.3 1.87
Tubb3 tubulin, beta 3 Mm.40068 – 1.62
Mapk10 mitogen activated protein
kinase 10
Mm.4936 – 1.62
Arhgef3 Rho guanine
nucleotide exchange
Mm.34514 – 1.62
Scg3 secretogranin III Mm.2386 – 1.52
Mapt microtubule-associated
protein tau
Mm.1287 – 1.41
Dlx1 distal-less homeobox 1 Mm.4543 – 1.41
Pcdha1 protocadherin alpha 1 Mm.192215 – 1.41
Etv1 ets variant gene 1 Mm.4866 – 1.41
Ret ret proto-oncogene Mm.57199 1.2 1.32
Uchl1 ubiquitin carboxy-terminal
hydrolase L1
Mm.29807 – 1.32
Tagln3 transgelin 3 Mm.24183 1.7 1.32
Nsg2 neuron specific gene
family member 2
Mm.3304 1.9 1.23
The newly identified GDNF responsive genes are in bold.
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after GDNF treatment (Table 2, bold).
3.2. GDNF up-regulates expression of PK-R1 in enteric NCCs
GPR73, also called Prokineticin receptor-1 (PK-R1), is a
receptor for prokineticins. Our recent study showed that
Prokineticin-1 (Prok-1) binds to PK-R1 to moderate the pro-
liferation and differentiation of enteric NCCs [17]. Therefore, it is
of particular interest to study the possible cross-talk between Prok-
1 and GDNF signalings. In our Affymetrix microarray analysis,PK-R1 was up-regulated by GDNF at both 8- and 16-h treatment
groups. We then validated this finding using an in vitro NCC
culture. p75NTR+ NCCs were sorted out from the dissociated
mouse embryonic gut (E11.5) and then plated at clonal density in
accordance with a previously-described protocol [17,18]. The
differentiation capability of the isolated NCCs was confirmed by
immunohistochemistry and RT-PCR using various differentiation
and neural crest markers (Supplement 1). Consistent with our
microarray data, the expression level of PK-R1 was elevated by
1.8 and 2.1 folds after 8-h and 16-h treatment with GDNF,
respectively, as evident in the semi-quantitative RT-PCR (Fig. 1A,
top panel) and qPCR analyses (Fig. 1A, bottom panel).
It is known that activations of MAPK and Akt transduction
pathways are crucial for GDNF functions. To identify the path-
ways responsible for the GDNF induced receptor expression,
NCCs were treated with GDNF (50 ng/ml) in the presence or
absence ofMAPK (20 μMPD98059) or Akt (10 μMLY294002)
Fig. 1 (continued ).
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PK-R1 transcript expression. Surprisingly, MAPK and Akt
inhibitors not only inhibited the GDNF induced PK-R1 ex-
pression, but also completely abrogated the endogenous PK-R1
expression in NCCs (Fig. 1B).3.3. Down-regulation of PK-R1 in c-Ret deficient mice
Evidently, GDNF up-regulates PK-R1 expression in enteric
NCCs. To further confirm this observation in vivo, c-Ret
deficient mouse embryos (E14.5) were collected and the
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immunohistochemistry. As marked by Tuj1 antibody, mice
homozygous for a targeted mutation of c-Ret (Ret.k−) lack
enteric ganglia posterior to the proximal stomach and exhibit
intestinal aganglionosis as described previously [6]. Immuno-
signal specific for PK-R1 was detected in the Tuj1+ NCCs
locating at the stomach of wild-type and homozygous (Ret.k−/
Ret.k−) mutant mouse embryos (Fig. 1C). Noteworthy, weaker
immunosignals were consistently found in homozygous (Ret.k−/
Ret.k) mouse embryos (Fig. 1C, f–h). It further supports the idea
that GDNF signaling mediates the in vivo expression of PK-R1.
3.4. Vasoactive intestinal polypeptide (VIP) and olfactomedin 1
(Olfm1) are the common downstream targets for GDNF and
Prok-1 signalings
Both GDNF and Prok-1 mediate proliferation and differen-
tiation of NCCs by activating Akt and MAPK signalings
[17,22]. The functional redundancy and signaling overlapping
of these two growth factors may imply that they share the
common downstream targets. As shown in the microarray
screening and RT-PCR, both VIP and Olfm1 were the immediate
targets for GDNF signal and up-regulated by GDNF (16 h) in
enteric NCCs (Table 2 and Fig. 2A). Similarly, Prok-1 also up-
regulated the expression of these two genes in the enteric NCCs
(Fig. 2B). In addition, the Prok-1 induced up-regulations were
reduced by PK-R1 knock-down using PK-R1 siRNA whenFig. 2. GDNF and Prok-1 up-regulates VIP and Olfm1. RT-PCR analysis on the VIP a
for 16 h. NCCs were then harvested for the total RNA extraction and reverse trans
ethidium bromide, photographed. β-actin was used as the internal control. (C) RT-PC
24 h after transfection with PK-R1 siRNA and the non-silencing control (Ctrl) in p
reported in bar charts represent the mean±SEM of 2 independent assays, each in dup
Bars bearing ⁎⁎ are statistically different from the non-silencing control (Ctrl NS, pcompared to the non-silencing control (NS) (Fig. 2C). It suggests
that Prok-1 and GDNF not only share the intracellular media-
tors of signaling pathways, but also some of the downstream
targets.
3.5. Additive effects of Prok-1 and GDNF in the proliferation
and differentiation of enteric NCCs
To examine the possible functional interaction between
GDNF and Prok-1 signaling pathways, enteric NCCs treated
with vehicle, Prok-1 alone, GDNF alone or in combination were
subjected to BrdU incorporation assays. GDNF (50 ng/ml) and
Prok-1 (4 μg/ml) alone increased the proliferation of NCCs
from 26.8±2.1% to 37.5±4.1% and to 35.1±1.9%, respective-
ly. A combination of Prok-1 and GDNF, on the other hand,
could significantly increase the number of proliferative NCCs
up to 62.5±1.0% (pb0.05) (Fig. 3A). The additive effect of
Prok-1 and GDNF in mediating NCCs proliferation was
significantly reduced by PK-R1 siRNA (Fig. 3B).
In addition to proliferation, both Prok-1 and GDNF confer
NCCs the ability to form neurons. To further assess the possible
interaction of Prok-1 and GDNF in inducing differentiation of
NCCs, Prok-1 and GDNF were administrated to NCC culture
alone or in combination for 3 days. It was found that NCCs
aggregate together and express neuron-specific marker, beta-
tubulin (Tuj1+) after GDNF or Prok-1 treatment (Fig. 4A, d and
d’). More importantly, a significant increase in number ofnd Olfm1 expression. NCCs were cultured with vehicle, (A) GDNF or (B) Prok-1
cription. PCR products were electrophoresed on 1% agarose gel, stained with
R and (D) qPCR analyzes on the expression of PK-R1, VIP and Olfm1 in NCCs
resence or absence of Prok-1. 18S was used as the internal control. The values
licate. Data were analyzed by one-way ANOVA followed by the Tukey posttest.
b0.05).
Fig. 3. Prok-1 enhances GDNF induced proliferation. (A) Representative pictures from BrdU incorporation and immunocytochemical assays show the combinatory
effect of Prok-1 and GDNF on the proliferation of NCCs. NCCs were treated with (a) vehicle, (b) Prok-1 alone, (c) GDNF alone or (d) combined treatment for 24 h.
Then, NCCs were stained with anti-Ret antibody (Red) and proliferating cells were detected with anti-BrdU antibody (Green). Bar 100 μm. (B) PK-R1 siRNA
abolishes the proliferative effect of Prok-1. NCCs were treated with vehicle, Prok-1 and GDNF for 24 h in presence of either PK-R1siRNA or non-silencing control
(NS Ctrl). Proliferating cells were incorporated with BrdU and the relative proliferation rates were measured by counting proliferative NCCs (Ret+, BrdU+) over the
total number of NCCs (Ret+). The values reported in bar charts represent the mean±SEM of 2 independent assays, each in duplicate. Data were analyzed by one-way
ANOVA followed by the Tukey posttest. Bars bearing ⁎⁎ are statistically different from the non-silencing control (Ctrl NS, pb0.05).
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GDNF and Prok-1 was used (Fig. 4A and B).
Subsequent expression analysis indicated that Prok-1, like
GDNF, elevates the expression of neuronal markers such as VIP
and Stmn2. Nevertheless, only GDNF (but not Prok-1) was able
to up-regulate Scg3, Galn and Gdap1 expression in NCCs.
Consistently, a combinatorial effect of Prok-1 and GDNF was
also observed by the augmented expression of these differen-
tiation markers. As revealed by quantitative RT-PCR analysis,
significant higher expression levels of VIP and Stm2 were
found in GDNF+Prok-1 treated NCCs when compared to thosetreated with GDNF or Prok-1 alone (Fig. 4B). Taken together, it
suggests that Prok-1 does not only promote the aggregation, but
also the differentiation.
3.6. Prok-1 induces proliferation and differentiation of c-Ret
deficient NCCs
NCCs were isolated from E11.5 c-Ret deficient mouse
embryos and the wild-type littermates and enriched by culturing
with NCC culture medium and repeated replating at the clonal
density as described [17]. Compared to NCCs from the wild-
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homozygous Ret.k−/− mice and their sizes were smaller.
Consistently, subsequent proliferation assay indicated that Ret.k−/− NCCs grows slower than the wild-type NCCs (Fig. 5A and
B). Importantly, Prok-1 still increased the proliferation of Ret
deficient (Ret−/−) NCCs as seen in the wild-type NCCs when
Fig. 4. Prok-1 increases the GDNF induced expression of differentiation
markers. (A) Prok-1 enhances GDNF induced expression of neuronal markers in
NCCs. Representative pictures from immunocytochemical analysis of (a, a')
untreated, (b, b') GDNF, (c, c') Prok-1 and (d, d') GDNF+Prok-1 treated NCCs.
NCCs were cultured in the presence of vehicle or GDNF, Prok-1 and
incombination for 72 h. Then, the cells were subjected to immunocytochemical
analysis using antibodies specific to Tuj1 (a, b, c, d) and counterstained with
DAPI (a', b', c', d'). Bar 100 μm. The boxed areas are magnified and shown in
the corner of the corresponding panels. (B) Quantitative analysis on the Tuj1
positive cells in different treatment groups. Data are mean±SEM of 2
independent assays, each in duplicate. Bars bearing different letters are
statistically different (pb0.05). (C) Real-time RT-PCR analysis on the
expression of a panel of GDNF target genes. cDNAs from NCCs treated with
vehicle, GDNF, Prok-1 or in combination were used to examine the expression
levels of VIP, Stmn2, Scg3, Galn and Gdap1 using qPCR. The bar charts
represent the data from the qPCR analysis of the mean expression relative to
internal standard after normalization with 18S expression. The values reported in
bar charts represent the mean±SEM of 2 independent assays, each in duplicate.
Bars bearing different letters are statistically different (pb0.05).
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2.8%; WT±Prok1: 39.5±2.5%; Ret−/−: 13.2±1.8% and Ret−/− +
Prok-1: 22.4±1.5%) (Fig. 5B).
In regard to the differentiation capability, it was shown that
Prok-1 up-regulates the expressions of two differentiation
markers (VIP and Stmn2) in both Ret−/− and wild-type NCCs,
suggesting that Prok-1 mediates differentiation of NCCs
independently of the GDNF/Ret signalings (Fig. 5C). In
addition, it is also noted that Ret−/− NCCs persistently expressed
lower level of PK-R1 transcript than that of the wild-type
NCCs, and Prok-1 could only elevate expression of PK-R1
slightly (Fig. 5D). Nevertheless, functionally, Prok-1 cannot
fully compensate for the loss of GDNF/Ret signal. Ret−/− NCCs
still proliferated slower and expressed lower level of differen-
tiation markers than that of the wild-type NCCs even in pre-
sence of Prok-1.
4. Discussion
Prokineticins have been implicated in stem cell survival/
growth by modulating the proliferation/survival and differen-
tiation of various progenitor cells, including hematopoietic stem
cells [23,24], neural stem cells [25,26] as well as NCCs [17].
Prok-1, in particular, plays a pivotal role in the development of
the peripheral nervous systems from NCCs. It promotes not
only the proliferation and differentiation of enteric NCCs [17],
but also migration of neuroblastoma cells which are derived
from NCCs of sympathetic nervous system [27]. Such a role is
further supported by observation that aberrant Prok-1 signaling
is associated with the development of neuroblastoma [27].
As for the enteric NCCs, we have previously shown that
Prok-1 shares similar properties to those of GDNF signaling,
including mediating proliferation and differentiation, reflecting
the parallels between GDNF and Prok-1 signalings (Fig. 6). In
the present study, we noted that activation of Prok-1 signaling
did not contribute equally to modulation of all forms of GDNF
responses, but they at least share some common downstream
targets which are known to be crucial for NCC growth (Olfm1)
and differentiation (VIP and Stmn2). Olfm1 is a secreted protein
which is expressed in both neural tube and migrating neural
crest cells and plays key roles in conferring on neural tube the
ability to generate neural crest and promote neurogenesis
[19,28]. VIP is a neuropeptide which is expressed in the
terminally differentiated neurons of developing ENS, while
Stmn2 is responsible for axon outgrowth [15]. The redundancy
of Prok-1 and GDNF also supports the idea that Prok-1 provides
an additional pathway to enhance the proper development of
ENS. When conditions are unfavorable to GDNF function, as
they probably are in cases of Ret mutation(s) or reduced GDNF
expression, Prok-1 would provide an additional layer of control
to ensure the proper development of ENS. As we demonstrated
in the c-Ret deficient mice and Ret−/− NCCs, PK-R1 is still
expressed, but at lower level. Prok-1, in certain extent, still
induces proliferation and differentiation of NCCs independently
of the Ret signaling. This may imply that Prok-1 signaling is in
part responsible for maintaining the survival and differentiation
of NCCs in the stomach. Nevertheless, unlike GDNF, Prok-1 is
Fig. 5. Prok-1 mediates proliferation and differentiation of NCCs independent of GDNF/Ret signaling. Immunocytochemical analyzes show Prok-1 increases the
proliferation of WT and Ret−/− NCCs. Wild-type (WT) (a, c) and Ret−/− NCCs (b, d) were treated with vehicle or Prok-1 for 24 h. Proliferating cells had been
incorporated with BrdU; then the relative proliferation rate was measured by (A) immunocytochemical analysis using anti-BrdU antibody. (B) The values reported in
bar charts represent the mean±SEM of 2 independent assays, each in duplicate. Data were analyzed by one-way ANOVA followed by the Tukey posttest. Bars bearing
⁎⁎ are statistically different from the vehicle control (Vehicle, pb0.05). (C) RT-PCR (D) and qPCR analyzes show Prok-1 up-regulates the expression of differentiation
markers (VIP, Stmn2). β-actin and 18S were used as internal controls for RT-PCR and qPCR, respectively. The values reported in bar charts represent the mean±SEM
of 2 independent assays, each in duplicate. Data were analyzed by one-way ANOVA followed by the Tukey posttest. Bars bearing ⁎⁎ are statistically different from the
non-silencing control (Ctrl NS, pb0.05).
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which may account for why Prok-1 cannot fully compensate the
loss of GDNF.
We have also shown that GDNF coordinates its functions
with Prok-1 by up-regulating PK-R1 expression. In the in vitro
culture, GDNF induced PK-R1 expression was observed asearly as at 8 h after treatment, suggesting that it is likely a direct
effect of GDNF. RT-PCR analysis also showed that abrogation
of MAPK or Akt pathways results in a complete suppression of
PK-R1 expression, both the endogenous and GDNF induced
expression, implying that both MAPK and Akt pathways are
essential for PK-R1 expression (Fig. 6). Indeed, we found at
Fig. 6. Schematic diagram shows the cross-talk between GDNF/Ret and Prok-1
signaling pathways. Both GDNF and Prok-1 activate MAPK and Akt signaling
to induce proliferation/differentiation of NCCs. In addition, GDNF enhances
Prok-1 signaling by up-regulation of PK-R1 expression. Addition of MAPK and
Akt inhibitors (PD98059 and LY294002) reduces the endogenous and GDNF-
induced PK-R1 expression.
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region of PK-R1. The activation of the activating protein-1 (AP-1)
family of transcription factors, including c-Fos and c-Jun family
members, was shown as one of the earliest nuclear events induced
by growth factors that stimulate MAPK [29]. Therefore, it is also
possible that GDNF mediates PK-R1 expression by directly
activating c-Fos and c-Jun via MAPK activation. However,
further experiments are required to understand the underlying
regulatory mechanisms. In the c-Ret mutant mice, the expression
level of PK-R1 was consistently lower when compared to the
wild-typemice. It further confirms the idea of theGDNFmediated
expression of PK-R1 in vivo. Functionally, GDNF potentiates
Prok-1 induced proliferation and differentiation, probably via up-
regulating PK-R1, in turns increase the sensitivity of NCCs to
Prok-1. Since the effects of Prok-1 and GDNF on both
proliferation and differentiation could be abolished by MAPK
and Akt inhibitors [17,22], it is believed that MAPK and Akt
might also serve to integrate Prok-1/PK-R1 and GDNF/Ret
signalings. It is noteworthy that the two inducing factors together
have only little additive effects. This can be explained by the fact
that they act on the common downstream targets, such as Olfm1,
VIP and Stmn2.
Defects in NCCs may cause incomplete colonization of gut
and result in HSCR. Proliferation, migration and differentiation
are the three critical steps for the proper ENS development. In
particular, the cell proliferation make the precursor cells notonly in correct number and in full diversity, but also drives NCC
invasion of the intestine [1]. GDNF/Ret signaling has been
implicated in all these processes. Therefore, it is of particular
interest to identify Ret modifier gene(s), in turn, to delineate the
etiology of HSCR. In this study, we have provided solid
evidence of the potential functional crosstalk between Prok-1
and GDNF signalings. It suggests that Prok-1 is likely acts as
one of the modifiers for Ret signaling and may contribute to the
HSCR susceptibility. In fact, there is no report on pk-r1 null
mice exhibiting colonic aganglionosis or severe impaired gut
function[30]. In spite of the strong evolutionary conservation of
coding sequence among developmentally important genes,
significant human–mouse differences in embryonic expression
patterns have been described [31]. These differences may
explain why the inactivation of a mouse orthologue results in a
phenotype that is substantially different from the human disease
that it was intended to model [32]. Noteworthy, unlike in mice,
both forms of prokineticins (Prok-1 and Prok-2) and their
receptors (PK-R1 and PK-R2) contribute to the prokineticin
signaling in humans [27]. Interestingly, PROK2 maps to the
3p21 chromosomal region, known to harbor a HSCR
susceptibility locus that probably functions as a RET dependent
modifier [33]. PKR2 maps to 20p12.3, region comprising
several genes probably involved in neurodevelopment, includ-
ing SNAP25. Importantly, 20p deletions have been identified in
syndromic HSCR patients, some of whom were autistic [34].
Taken together, PROK2 and PKR2 would be the modifiers for
Ret signalling and are the excellent candidates for further study.
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